



HUA01-NP007 / 09/773,830

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application : Group Art Unit: Unknown
 Huang, Z. : Examiner: Unknown
 Serial No.: 09/773,830 : Attorney Docket /
 Filed: 1 February 2001 : HUA01-NP007

For: A Novel Peptide Antagonist of CXCR4 Derived from the N-Terminus of Viral Chemokine vMIP-II


Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION
 IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825.**

- (X) I hereby state, in accordance with the requirements of **37 C.F.R. §1.821(f)**, that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 C.F.R. §1.821(c) and (e)**, respectively are the same.
- (X) I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 C.F.R. §1.825(a)**, included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(b)**, is the same as the amended Sequence Listing.
- (X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,


Teng Li
Registration No. 47,748
Agent for Applicant
THOMAS JEFFERSON UNIVERSITY
1020 Walnut Street – Suite 620
Philadelphia, PA 19107-5587
Telephone: (215-503-0757)
Facsimile: (215-923-3613)

Date: 6/14/02